<DOC>
	<DOCNO>NCT01543867</DOCNO>
	<brief_summary>This study conduct Europe . The aim study evaluate safety long-term use somatropin ( NorditropinÂ® ) child well efficacy change height . A subgroup child small gestational age include .</brief_summary>
	<brief_title>Safety Efficacy Long-term Somatropin Treatment Children</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>In need somatropin current user</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>